Search - tctmd.com

Displaying 81 - 100 of 143

Sort: Relevancy | Date

News Daily News

Ethnic Variations in Lp(a) Concentrations Challenge Current Risk Thresholds

Yael L. Maxwell

January 25, 2019

News Daily News

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

Yael L. Maxwell

January 10, 2019

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Daily News

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Yael L. Maxwell

December 19, 2018

News Daily News

Lp(a) Might Not Be Good at Predicting Incident CVD in Low-Risk Women

Yael L. Maxwell

July 09, 2018

News Daily News

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

Yael L. Maxwell

June 25, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Conference News EAS 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Yael L. Maxwell

May 14, 2018

News Conference News EAS 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Yael L. Maxwell

May 11, 2018

News Conference News EAS 2018

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Yael L. Maxwell

May 08, 2018

News Conference News EAS 2018

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Yael L. Maxwell

May 07, 2018

News Conference News EAS 2018

Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

Yael L. Maxwell

May 07, 2018

News Daily News

Childhood Obesity Can Affect Cardiovascular Risk Even If Resolved by Adulthood

Yael L. Maxwell

April 11, 2018

News Daily News

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Yael L. Maxwell

March 28, 2018

News Daily News

Bempedoic Acid Phase III Trial Meets Primary Endpoint for Cutting LDL Cholesterol

Yael L. Maxwell

March 08, 2018

News Daily News

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Yael L. Maxwell

January 29, 2018

News Daily News

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Yael L. Maxwell

January 09, 2018

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

Advertisement

Ethnic Variations in Lp(a) Concentrations Challenge Current Risk Thresholds

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

Top News in Clinical Cardiology: 2018

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Lp(a) Might Not Be Good at Predicting Incident CVD in Low-Risk Women

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

Childhood Obesity Can Affect Cardiovascular Risk Even If Resolved by Adulthood

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Bempedoic Acid Phase III Trial Meets Primary Endpoint for Cutting LDL Cholesterol

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content